NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
The Research Plan: Closing the ExMC Med02 "Pharmacy" GapHRP Human Research Roadmap: Risk and Gap Risk of Adverse Health Outcomes and Decrements in Performance due to Inflight Medical Conditions. Med02 "Pharmacy" Gap: We do not have the capability to provide a safe and effective medication formulary for exploration missions delivering a recommendation for a chemically stable, safe, and effective medication formulary that will support the operational needs of exploration space missions research strategy evidence-based formulary and models innovative analytical tools and methodologies novel treatments and preventive measures Planned review by a panel of experts from the pharmaceutical industry, regulatory, and academic scientific communities Formulary Selection Formulary Potency and Shelf life Formulary Safety and Toxicity Novel Technology Proof-of-Concept Portable real-time chemical analysis Innovative drug development / design
Document ID
20170000795
Acquisition Source
Johnson Space Center
Document Type
Presentation
Authors
Daniels, Vernie
(KBRwyle Science, Technology and Engineering Houston, TX, United States)
Bayuse, Tina
(Wyle Labs., Inc. Houston, TX, United States)
Mulcahy, Robert
(Wyle Labs., Inc. Houston, TX, United States)
Shah, Ronak
(NASA Johnson Space Center Houston, TX, United States)
Antonsen, Erik
(NASA Johnson Space Center Houston, TX, United States)
Date Acquired
January 25, 2017
Publication Date
January 23, 2017
Subject Category
Aerospace Medicine
Report/Patent Number
Report Number: JSC-CN-38525
JSC-CN-38525
Meeting Information
Meeting: 2017 NASA Human Research Program Investigators'' Workshop (HRP IWS 2017) Annual Meeting
Location: Galveston, TX
Country: United States
Start Date: January 23, 2017
End Date: January 26, 2017
Sponsors: NASA Johnson Space Center, National Space Biomedical Research Inst. (NSBRI)
Distribution Limits
Public
Copyright
Public Use Permitted.
No Preview Available